keyword
MENU ▼
Read by QxMD icon Read
search

Double blind

keyword
https://www.readbyqxmd.com/read/29050397/the-antimyotonic-effect-of-lamotrigine-in-non-dystrophic-myotonias-a-double-blind-randomized-study
#1
Grete Andersen, Gitte Hedermann, Nanna Witting, Morten Duno, Henning Andersen, John Vissing
Mexiletine is the only drug with proven effect for treatment of non-dystrophic myotonia, but mexiletine is expensive, has limited availability and several side effects. There is therefore a need to identify other pharmacological compounds that can alleviate myotonia in non-dystrophic myotonias. Like mexiletine, lamotrigine is a sodium channel blocker, but unlike mexiletine, lamotrigine is available, inexpensive, and well tolerated. We investigated the potential of using lamotrigine for treatment of myotonia in patients with non-dystrophic myotonias...
September 1, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29050384/stimulating-thought-a-functional-mri-study-of-transcranial-direct-current-stimulation-in-schizophrenia
#2
Natasza D Orlov, Owen O'Daly, Derek K Tracy, Yusuf Daniju, John Hodsoll, Lorena Valdearenas, John Rothwell, Sukhi S Shergill
Individuals with schizophrenia typically suffer a range of cognitive deficits, including prominent deficits in working memory and executive function. These difficulties are strongly predictive of functional outcomes, but there is a paucity of effective therapeutic interventions targeting these deficits. Transcranial direct current stimulation is a novel neuromodulatory technique with emerging evidence of potential pro-cognitive effects; however, there is limited understanding of its mechanism. This was a double-blind randomized sham controlled pilot study of transcranial direct current stimulation on a working memory (n-back) and executive function (Stroop) task in 28 individuals with schizophrenia using functional magnetic resonance imaging...
September 1, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29049653/effect-of-oral-semaglutide-compared-with-placebo-and-subcutaneous-semaglutide-on-glycemic-control-in-patients-with-type-2-diabetes-a-randomized-clinical-trial
#3
Melanie Davies, Thomas R Pieber, Marie-Louise Hartoft-Nielsen, Oluf K H Hansen, Serge Jabbour, Julio Rosenstock
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection. Objectives: To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes. Design, Setting, and Patients: Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014...
October 17, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29048765/ageratum-conyzoides-l-inhibits-5-alpha-reductase-gene-expression-in-human-prostate-cells-and-reduces-symptoms-of-benign-prostatic-hypertrophy-in-otherwise-healthy-men-in-a-double-blind-randomized-placebo-controlled-clinical-study
#4
Matthew Detering, Elizabeth Steels, Sundar Rao Koyyalamudi, Elena Allifranchini, Elena Bocchietto, Luis Vitetta
A double-blind, randomized, placebo-controlled clinical trial assessed the efficacy and safety of Ageratum conyzoides in treating benign prostatic hypertrophy (BPH). In this study, 109 men with medically diagnosed BPH, aged 41-76 years, were administered the investigational product, A. conyzoides extract at a dose of 250 mg/d or placebo, q.d. for 12 weeks. The primary outcome measures were the International Prostate Symptom Score (IPSS), daily urinary frequency and safety evaluations. The secondary outcome measures were testosterone, dihydrotestosterone, oestradiol, sex hormone binding globulin (SHBG), Dehydroepiandrosterone sulfate (DHEA-S) and cortisol levels, and prostate specific antigen (PSA), lipids, blood glucose, the Aging Male's Symptom (AMS) Score and sexual function assessed by Derogatis Interview for Sexual Functioning-Self Report (DISF-SR)...
October 19, 2017: BioFactors
https://www.readbyqxmd.com/read/29048132/comparison-of-the-efficiency-of-ultrasound-guided-injections-of-the-rhomboid-major-and-trapezius-muscles-in-myofascial-pain-syndrome-a-prospective-randomized-controlled-double-blind-study
#5
Burcu Metin Ökmen, Korgün Ökmen, Lale Altan
OBJECTIVES: We aimed to investigate the effect of ultrasound (US)-guided injections of the rhomboid major (deep) and trapezius (superficial) muscles on pain, disability, and quality of life in patients with myofascial pain syndrome. METHODS: In this prospective randomized controlled double-blind study, 65 patients with a diagnosis of myofascial pain syndrome were randomized into 2 groups. In group 1 (n = 33), US-guided rhomboid major muscle injection was performed, and in group 2 (n = 32), US-guided trapezius muscle injection was performed...
October 19, 2017: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/29047408/the-efficacy-of-the-kampo-medicine-rikkunshito-for-chemotherapy-induced-anorexia-rich-trial-study-protocol-for-a-randomized-controlled-trial
#6
Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroshi Yokouchi, Kenya Kanazawa, Katsuya Ohbuchi, Takahisa Fukushima, Mitsuru Munakata, Hiroyuki Suzuki
BACKGROUND: Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea and vomiting, anorexia, and weight loss. These symptoms sometimes affect patients' quality of life and make continuation of chemotherapy difficult. Anorexia is a cause of concern for patients with cancer because a persistent loss of appetite progresses to cancer cachexia. Although evidence-based management for chemotherapy has recently been established, there is room for improvement...
October 18, 2017: Trials
https://www.readbyqxmd.com/read/29047215/acute-cardiovascular-effects-of-bitter-orange-extract-p-synephrine-consumed-alone-and-in-combination-with-caffeine-in-human-subjects-a-placebo-controlled-double-blind-study
#7
Nicholas A Ratamess, Jill A Bush, Sidney J Stohs, Nicole L Ellis, Ira T Vought, Elizabeth A O'Grady, Jeremy D Kuper, Saif B Hasan, Jie Kang, Avery D Faigenbaum
The purpose was to examine cardiovascular responses to supplementation with p-synephrine alone and in combination with caffeine during quiet sitting. Sixteen subjects were given (in double-blind manner) either 103 mg of p-synephrine (S), 233 mg of caffeine +104 mg of p-synephrine (LC + S), 240 mg of caffeine (LC), 337 mg of caffeine +46 mg of p-synephrine (HC + S), 325 mg of caffeine (HC), or a placebo. The subjects sat quietly for 3 hr while heart rate (HR) and blood pressure were measured. Only HC + S and HC significantly increased mean systolic blood pressure (SBP) during the second hour and tended to increase mean SBP during the third hour...
October 19, 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/29047183/follow-up-of-patients-with-uncertain-symptoms-during-an-oral-food-challenge-is-useful-for-diagnosis
#8
Taro Miura, Noriyuki Yanagida, Sakura Sato, Kiyotake Ogura, Motohiro Ebisawa
BACKGROUND: Uncertain symptoms often emerge during an oral food challenge (OFC) and Open-OFCs with those uncertain mild symptoms are ordinarily regarded as positive. Double-blind placebo-controlled food challenges should be conducted in order to determine these associations. Nevertheless, studies regarding the diagnosis of uncertain food allergy symptoms are lacking. We examined the diagnostic decision for a food allergy based on uncertain symptoms during an Open-OFC. METHODS: We conducted an Open-OFC between August 2005 and April 2012 with 2271 cases who suspected as allergic to hen's eggs, cow's milk, or wheat...
October 19, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29047178/the-effect-of-montelukast-on-early-life-wheezing-a-randomized-double-blinded-placebo-controlled-study
#9
Ozlem Keskin, Ebru Arik Yilmaz, Christine Motzkus, Cansin Sackesen, Craig M Lilly, Omer Kalayci
BACKGROUND: Cysteinyl-leukotrienes are increased in the airways of infants with virus-associated wheezing. We aimed to determine the effects of a cysteinyl-leukotriene-1 receptor antagonist on symptoms during an early-life wheezing illness and to investigate the factors that affect the response to this drug. METHOD: This placebo-controlled double-blinded randomized controlled trial recruited children aged 3-36 months with wheezing illness and randomized to active drug or placebo for 56 days...
October 19, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29046301/bone-mineral-density-during-pregnancy-in-women-participating-in-a-randomized-controlled-trial-of-vitamin-d-supplementation
#10
Wei Wei, Judith R Shary, Elizabeth Garrett-Mayer, Betsy Anderson, Nina E Forestieri, Bruce W Hollis, Carol L Wagner
Background: Little is known about bone mineral density (BMD) during pregnancy. Advances in technology with lower radiation emissions by dual-energy X-ray absorptiometry instruments now permit the safe measurement of BMD during pregnancy.Objective: We evaluated maternal BMD during pregnancy as a function of vitamin D status in women of diverse racial/ethnic backgrounds.Design: A total of 301 women who underwent BMD measurements at 12-20 wk of gestation and again at 0-14 wk postpartum were included in this analysis...
October 18, 2017: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/29045769/placebo-effects-in-the-treatment-of-noncognitive-symptoms-of-alzheimer-s-disease-analysis-of-the-catie-ad-data
#11
Chisa Ozawa, Rachel Roberts, Kazunari Yoshida, Takefumi Suzuki, Barry Lebowitz, Suzanne Reeves, Robert Howard, Takayuki Abe, Masaru Mimura, Hiroyuki Uchida
OBJECTIVE: To compare symptom trajectories between placebo and active drug responders and to examine whether early placebo improvement would be associated with subsequent placebo response in the treatment of patients with behavioral and psychological symptoms of dementia. METHODS: A post hoc analysis of data from 371 patients with DSM-IV Alzheimer's disease in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness for Alzheimer's disease (CATIE-AD) (April 2001 to November 2004) was conducted...
October 17, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29045584/oxytocin-fails-to-recruit-serotonergic-neurotransmission-in-the-autistic-brain
#12
Arthur Lefevre, Raphaëlle Mottolese, Jérôme Redouté, Nicolas Costes, Didier Le Bars, Marie-Maude Geoffray, Marion Leboyer, Angela Sirigu
Oxytocin (OT), a neuropeptide involved in affiliation has been shown to enhance social skills in patients with autism spectrum disorders (ASD). Nevertheless, OT improvements seem ephemeral. Animal research has demonstrated OT action on serotonin (5-HT), an interaction that we also found in the healthy human brain. Whether such synaptic interplay also occurs in ASD patients is unknown. To address this issue, we mapped the effects of intranasal OT on 5-HT in 18 patients with ASD and 24 healthy controls (HC) in a double blind, placebo controlled, within subject PET-scan experiment...
October 17, 2017: Cerebral Cortex
https://www.readbyqxmd.com/read/29045535/select-2-a-phase-ii-double-blind-randomised-placebo-controlled-study-to-assess-the-efficacy-of-selumetinib-plus-docetaxel-as-a-second-line-treatment-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer
#13
J C Soria, A Fülöp, C Maciel, J R Fischer, G Girotto, S Lago, E Smit, G Ostoros, W E E Eberhardt, P Lishkovska, S Lovick, G Mariani, A McKeown, E Kilgour, P Smith, K Bowen, A Kohlmann, D J Carlile, P A Jänne
Background: Combination of selumetinib plus docetaxel provided clinical benefit in a previous Phase II trial for patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC). The Phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. Patients and methods: Patients who had disease progression after first-line anti-cancer therapy were randomised (2:2:1) to selumetinib 75 mg BID plus docetaxel 60 mg/m2 or 75 mg/m2 (SEL+DOC 60; SEL+DOC 75), or placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)...
October 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045520/overall-survival-analysis-of-exam-a-phase-3-trial-of-cabozantinib-in-patients-with-radiographically-progressive-medullary-thyroid-carcinoma
#14
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle, E E W Cohen, L Wirth, H Ali, D O Clary, Y Yaron, M Mangeshkar, D Ball, B Nelkin, S Sherman
Background: Primary analysis of the double-blind, phase 3 EXAM trial demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was performed after long-term follow-up. Patients and Methods: EXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC...
September 22, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045341/effect-of-antihypertensive-treatment-on-24-h-blood-pressure-variability-pooled-individual-data-analysis-of-ambulatory-blood-pressure-monitoring-studies-based-on-olmesartan-mono-or-combination-treatment
#15
Stefano Omboni, Kazuomi Kario, George Bakris, Gianfranco Parati
OBJECTIVE: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 double-blind, randomized, ambulatory BP monitoring (ABPM) studies. METHODS: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n = 119), active control monotherapy [n = 1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)], or DCCBs), olmesartan monotherapy (n = 1410), active control dual combination [n = 79, DCCB + thiazide diuretic (TD)], olmesartan dual combination (n = 637, DCCB or TD), and triple combination therapy (n = 102, DCCB+TD)...
October 16, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/29045315/a-single-dose-of-oral-atp-supplementation-improves-performance-and-physiological-response-during-lower-body-resistance-exercise-in-recreational-resistance-trained-males
#16
Marcelo C Freitas, Jason M Cholewa, Jose Gerosa-Neto, Daniela C Gonçalves, Erico C Caperuto, Fábio S Lira, Fabrício E Rossi
The aim of this study was to investigate the acute effect of ATP supplementation on performance and physiological responses during resistance exercise in recreationally resistance trained males. Eleven men (age= 27.5±5.5 yrs, weight= 83.4±9.8 kg, height= 182±0.04 cm) completed two randomized, double-blind trials: ATP supplement condition (ATP=400mg) or a placebo condition. Thirty minutes after supplement consumption, subjects performed four sets of half-squats until momentary muscular failure at 80% of the 1RM with two minutes of recovery between sets...
October 16, 2017: Journal of Strength and Conditioning Research
https://www.readbyqxmd.com/read/29045255/listening-to-relaxing-music-improves-physiological-responses-in-premature-infants-a-randomized-controlled-trial
#17
Rafael A Caparros-Gonzalez, Alejandro de la Torre-Luque, Carolina Diaz-Piedra, Francisco J Vico, Gualberto Buela-Casal
BACKGROUND: Premature infants are exposed to high levels of noise in the neonatal intensive care unit (NICU). PURPOSE: This study evaluated the effect of a relaxing music therapy intervention composed by artificial intelligence on respiratory rate, systolic and diastolic blood pressure, and heart rate. METHODS: A double-blind, randomized, controlled trial was conducted in the NICUs of 2 general public hospitals in Andalusia, Spain. Participants were 17 healthy premature infants, randomly allocated to the intervention group or the control group (silence) at a 1:1 ratio...
October 17, 2017: Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses
https://www.readbyqxmd.com/read/29045212/tofacitinib-or-adalimumab-versus-placebo-for-psoriatic-arthritis
#18
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs). METHODS: In this 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial, we randomly assigned patients in a 2:2:2:1:1 ratio to receive one of the following regimens: tofacitinib at a 5-mg dose taken orally twice daily (107 patients), tofacitinib at a 10-mg dose taken orally twice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), placebo with a blinded switch to the 5-mg tofacitinib dose at 3 months (52), or placebo with a blinded switch to the 10-mg tofacitinib dose at 3 months (53)...
October 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29045207/tofacitinib-for-psoriatic-arthritis-in-patients-with-an-inadequate-response-to-tnf-inhibitors
#19
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors. METHODS: In this 6-month randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 months (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 months (65 patients)...
October 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29044968/a-prospective-randomised-placebo-controlled-study-of-the-impact-of-dutasteride-tamsulosin-combination-therapy-on-sexual-function-domains-in-sexually-active-men-with-lower-urinary-tract-symptoms-luts-secondary-to-benign-prostatic-hyperplasia-bph
#20
Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson, Erik Pm Roos, Javier Cambronero Santos, Dimitrios Karanastasis, Janet Plastino, Francois Giuliano, Raymond C Rosen
OBJECTIVE: To prospectively assess the impact of the fixed-dose combination of the 5-alpha reductase inhibitor (5ARI), dutasteride 0.5 mg and the alpha-1 blocker, tamsulosin 0.4 mg (DUT-TAM FDC) therapy on sexual function domain scores in sexually active males with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), using the Men's Sexual Health Questionnaire (MSHQ). PATIENTS AND METHODS: This European and Australian double-blind, placebo-controlled, parallel-group study was conducted at 51 centres...
October 16, 2017: BJU International
keyword
keyword
44026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"